An interventional study of progesterone vaginal sustained-release gel in Infertility, Female, sponsored by Nanjing University. Recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-08-22.
Sponsored by Nanjing University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Infertility, Female with a site in China — 17 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.
Among the 58 studies in Infertility, Female with a site in China, this one is the 28th largest by planned enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2023, is one of 32 with no phase, reaches primary completion later than 0 of the 19 other live ones, and was the 40th registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →17 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Shandong University of Traditional Chinese Medicine · Sites in China
Ages 21–44 · Women only
Tang-Du Hospital · Sites in China
Ages 20–40 · Women only
Suzhou Centergene Pharmaceuticals Co.,Ltd. · Sites in China
Ages 20–40 · Women only · Healthy volunteers
Peking University Third Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 1 · Phase 3 6 · Phase 4 4
First in 2014; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 152 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 178 across the 51 interventional studies, 2,569 across the 7 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 58 have an industry lead sponsor. The 10 most frequent:
Nanjing University is the lead sponsor of 21 studies on the registry; 9 are open to participants now.
Nanjing University has 5 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
4 of the studies in Infertility, Female with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06644794Phase 3Shandong University of Traditional Chinese MedicineProgesterone-modified Natural Cycle for FET | 2027-09-10 |
| NCT06775093Peking University Third HospitalEffects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | 2026-12-31 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07409792Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityMultifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes | 2027-01-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Infertility, Female with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-center, randomized, controlled prospective study. Those patients with repeated implantation failure (RIF) who will recieve frozen thawed embryo transfer (FET) are enrolled in the study. To determine the effect of vaginal progesterone on the clinical pregnancy outcomes of RIF patients.
According to the enrollment and exclusion criteria, the patients were enrolled, and the subjects were randomly divided into two groups by computer randomization. Group A was the vaginal progesterone added group (test group). Group B was the regular FET group (control group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Consistent with the diagnosis of repeated implantation failure of unknown reasons, the previous embryo transfer situation meets one of the following:
Total embryos transferred ≥ 4 high-quality cleavage-stage embryos; ≥ 2 blastocysts; ≥ 2 high quality cleavage-stage embryos +≥ 1 blastocysts;
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
90 mg progesterone vaginal sustained-release gel is added daily to induce endometrial transformation and luteal support
Drug: progesterone vaginal sustained-release gel
No additional vaginal progesterone gel, routine endometrial transformation and luteal support drugs
90 mg progesterone vaginal sustained-release gel is added daily during endometrial transformation and luteal support
Embryo implantation rate
The proportion of the number of implanted embryos to the total number of transferred embryos is the embryo implantation rate.
Time frame: 45 days after embryo transfer
Clinical pregnancy rate
Clinical pregnancy is defined as the presence of gestational sac observed by ultrasound. The proportion of clinical pregnancy cycles to total FET cycles is the clinical pregnancy rate.
Time frame: 45 days after embryo transfer
Early pregnancy loss rate
The early pregnancy loss rate refers to the proportion of patients with pregnancy loss before 12 weeks of gestation in the total clinical pregnancy patients.
Time frame: 12 weeks after embryo transfer
Persistent pregnancy rate
The ratio of the number of pregnancies lasting to 20 weeks to the number of transplant cycles.
Time frame: 20 weeks after embryo transfer
Live birth rate
The ratio of the number of live fetal delivery cycles to the number of transplantation cycles after 28 weeks of pregnancy.
Time frame: 40 weeks after embryo transfer
Started Aug 2023 (actual). Primary completion is estimated for Dec 2024, 16 months after the start.
Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 16 months is below that.
Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanjing University